Investorideas.com  big ideas for global investors Search www.investorideas.com
   Members       Sign-up       Newsfeeds        Companies        Stock Directories       Research       Video       Funding   




Category: Investment, Biotech, Biodefense

Medical Technology Research Alert: Zacks Small Cap Research Update for Aethlon Medical (OTCQB:AEMD); "Remain Encouraged By Ongoing Progress"

"Revenue came in in-line with our number with operating income coming in much better than our estimate"

Visit this company: www.aethlonmedical.com

Point Roberts, WA, New York, NY - August 20, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues a research alert for Aethlon Medical, Inc. (OTCQB: AEMD). Yesterday Brian Marckx, CFA from Zacks Small Cap Research issued an update on the company entitled, “Remain Encouraged By Ongoing Progress”.

Excerpt from Zacks Small Cap Research, Brian Marckx, CFA:

Aethlon Medical (OTC BB:AEMD) filed their 10-Q for the fiscal first quarter ending 6/30/2013 on August 13th. Revenue came in in-line with our number with operating income coming in much better than our estimate as a result of AEMD doing a nice job of cutting operating expenses and conserving resources. AEMD booked $196k in DARPA contract revenue in Q1 which was in-line with our number. Revenue relates to the twelfth milestone under the DARPA contract (the fourth milestone under the year-2 contract). Subsequent to the end of fiscal Q1 AEMD invoiced for and was paid another $404k which relates to the thirteenth and fourteenth milestones.

AEMD also disclosed in the 10-Q that they have submitted to Battelle their first invoice for work the company is doing under the previously announced subcontract agreement that the company has with Battelle related to the $22.8 million systems integrator contract with DARPA. AEMD's initial invoice is for just over $20k which we assume will be recorded and collected in fiscal Q2. As a reminder, AEMD's subcontract is a time and materials contract so the total that AEMD will eventually bill will not be known until their work is completed. We do, however, think it's likely that there will be additional revenue contribution from this contract throughout the year.

FullZacks Small Cap Research news :

http://finance.yahoo.com/news/aemd-remain-encouraged-ongoing-progress-110000029.html

3 month chart:

Investorideas.com Newswire

About Aethlon Medical (OTCQB: AEMD)

Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.

About InvestorIdeas.com: Big Ideas for global investors

InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.

Follow Investorideas.com on Twitterhttp://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com

Sign up for free stock alerts

http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech and medical technology stocks:

http://www.investorideas.com/membership/

Published at the Investorideas.com Newswire - Big ideas for Global Investors

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights.  Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by AEMD for news release distribution and content publishing: three thousand per month effective June 2013 More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

800-665-0411 or 212-822-8842 Source - www.Investorideas.com




Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner

TOP

Investor Ideas © 2000 - 2015 InvestorIdeas.com®, ECON

 

login | logout | about us | contact | disclaimer / disclosure |
partners / links | job search | privacy policy |
advertise | trade | sitemap |